SQUID Liquid Embolic Agent (LEA)
Balt USA, LLC · Decision date Sep 9, 2026
What did the FDA approve?
The FDA record for P250009/S002, dated 2026-09-09, shows an approval for changes to the mixing time for the SQUID Liquid Embolic Agent (LEA). It is classified as a real-time process supplement under the labeling-change reason covering indications, instructions, shelf life, or tradename. The record lists the device category as a neurovascular liquid embolic agent and the specialty as neurology, with Balt USA, LLC as applicant. The specific before-and-after mixing times are not given in the supplied fields.
The S002 identifier links the action to the preceding PMA P250009 as a supplement, not a new approval of the whole system. The record's reported purpose describes a process change to mixing time; it does not establish safety or clinical effectiveness independently. The supplied fields also omit whether the change is accompanied by revised labeling text, what prompted the change, and which shelf-life or instruction sections were affected.
The supplement type is listed as "Real-Time Process," and the stated purpose is confined to the mixing time, so no broader technical detail, trial result, or new indication should be inferred from this entry.
FDA approval order statement
Approval for changes to the mixing time for the SQUID Liquid Embolic Agent (LEA).
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Sep 9, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250009/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Balt USA, LLC
- Product code
- SGU
- Decision code
- APPR
- Decision date
- Sep 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Neurovascular Liquid Embolic Agent.
- Applicant
- Balt USA, LLC
- Product code
- SGU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250009 · Original PMA
SQUID Liquid Embolic Agent (LEA)
P250009/S002 received
Application receipt date recorded by FDA.
P250009/S002 · FDA decision
Real-Time Process
P250009/S001 · Related supplement
SQUID Liquid Embolic Agent (LEA)
Timeline entries are records held by MedtechLedger for P250009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Balt USA, LLC | PMA approval | Jan 30, 2026 | FDA | |
SQUID Liquid Embolic Agent (LEA)P250009/S001 | Balt USA, LLC | PMA supplement | Oct 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Balt USA, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 29 Parker, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250009/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
